Prognostic Significance of Pretreatment Apolipoprotein A-I as a Noninvasive Biomarker in Cancer Survivors: A Meta-Analysis

Table 3

Analyses of secondary outcomes for ApoA-I in cancers.

Secondary outcomes	No. of studies	No. of cases	Pooled HR (95% CI)	value	Heterogeneity
					I^2 (%)	Model
CSS	2	1666	0.47 (0.19–0.76)	<0.001	77.5	Random
TTR	2	443	0.43 (0.29–0.58)	<0.001	0.0	Fixed
LRFS	2	3123	0.58 (0.42–0.74)	<0.001	0.0	Fixed
DMFS	2	3123	0.65 (0.41–0.89)	<0.001	73.0	Random
DFS	4	3962	0.64 (0.43–0.84)	<0.001	65.9	Random